Back to results
US 2025/0367126 A1Published application
Softgel capsule comprising a h2 receptor antagonist
AssigneeKenvue Brands LLC
InventorsBruce P. Smith, Linus G. Fonkwe
Life of this patent
Estimating the term…
Abstract
The disclosure generally relates to soft gelatin oral dosage form. In particular the disclosure relates to an oral dosage form comprising a soft gelatin capsule and a liquid fill, where the liquid fill is a suspension of an H2 receptor antagonist in a hydrophobic/lipophilic excipient. The disclosure also relates to a method of treating a gastric disease or disorder by using said oral dosage form.
Claims13
An oral dosage form comprising a soft gelatin capsule and a liquid fill contained within the soft gelatin capsule,
- wherein the liquid fill comprises a suspension of an H2 receptor antagonist in a hydrophobic/lipophilic excipient substantially free from water, and
- wherein at least 50%, in wt %, of the hydrophobic/lipophilic excipient consists of linoleic acid or linoleate moiety.
Dependencies are inferred from the claim text.